The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs

With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatitis C (HCV), the concept of treatment as prevention is gaining credence. To date the majority of mathematical models assume perfect mixing with injectors having equal contact with all other injectors....

Full description

Bibliographic Details
Main Authors: Hellard, M., Rolls, D., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, Peter, Aitken, C., McBryde, E.
Format: Journal Article
Published: John Wiley & Sons Inc. 2014
Online Access:http://hdl.handle.net/20.500.11937/12592
_version_ 1848748116789952512
author Hellard, M.
Rolls, D.
Sacks-Davis, R.
Robins, G.
Pattison, P.
Higgs, Peter
Aitken, C.
McBryde, E.
author_facet Hellard, M.
Rolls, D.
Sacks-Davis, R.
Robins, G.
Pattison, P.
Higgs, Peter
Aitken, C.
McBryde, E.
author_sort Hellard, M.
building Curtin Institutional Repository
collection Online Access
description With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatitis C (HCV), the concept of treatment as prevention is gaining credence. To date the majority of mathematical models assume perfect mixing with injectors having equal contact with all other injectors. This paper explores how using a networks based approach to treat people who inject drugs (PWID) with DAAs affects HCV prevalence. Method: Using observational data we parameterized an Exponential Random Graph Model containing 524 nodes. We simulated transmission of HCV through this network using a discrete time, stochastic transmission model. The effect of five treatment strategies on the prevalence of HCV was investigated; two of these strategies were 1) treat randomly selected nodes and 2) “treat your friends” where an individual is chosen at random for treatment and all their infected neighbours are treated. Results: As treatment coverage increases, HCV prevalence at 10 years reduces for both the high efficacy and low efficacy treatment. Within each set of parameters, the “treat your friends” strategy performed better than the random strategy being most marked for higher efficacy treatment. For example over 10 years of treating 25 per 1000 PWID, the prevalence drops from 50% to 40% for the random strategy, and to 33% for the “treat your friends” strategy (6.5% difference, 95% CI 5.1 – 8.1%). Discussion: “Treat your friends” is a feasible means of utilising network strategies to improve treatment efficiency. In an era of highly efficacious and highly tolerable treatment such an approach will benefit not just the individual but the community more broadly by reducing the prevalence of HCV amongst PWID.
first_indexed 2025-11-14T06:59:56Z
format Journal Article
id curtin-20.500.11937-12592
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:59:56Z
publishDate 2014
publisher John Wiley & Sons Inc.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-125922019-02-19T05:34:47Z The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs Hellard, M. Rolls, D. Sacks-Davis, R. Robins, G. Pattison, P. Higgs, Peter Aitken, C. McBryde, E. With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatitis C (HCV), the concept of treatment as prevention is gaining credence. To date the majority of mathematical models assume perfect mixing with injectors having equal contact with all other injectors. This paper explores how using a networks based approach to treat people who inject drugs (PWID) with DAAs affects HCV prevalence. Method: Using observational data we parameterized an Exponential Random Graph Model containing 524 nodes. We simulated transmission of HCV through this network using a discrete time, stochastic transmission model. The effect of five treatment strategies on the prevalence of HCV was investigated; two of these strategies were 1) treat randomly selected nodes and 2) “treat your friends” where an individual is chosen at random for treatment and all their infected neighbours are treated. Results: As treatment coverage increases, HCV prevalence at 10 years reduces for both the high efficacy and low efficacy treatment. Within each set of parameters, the “treat your friends” strategy performed better than the random strategy being most marked for higher efficacy treatment. For example over 10 years of treating 25 per 1000 PWID, the prevalence drops from 50% to 40% for the random strategy, and to 33% for the “treat your friends” strategy (6.5% difference, 95% CI 5.1 – 8.1%). Discussion: “Treat your friends” is a feasible means of utilising network strategies to improve treatment efficiency. In an era of highly efficacious and highly tolerable treatment such an approach will benefit not just the individual but the community more broadly by reducing the prevalence of HCV amongst PWID. 2014 Journal Article http://hdl.handle.net/20.500.11937/12592 10.1002/hep.27403 John Wiley & Sons Inc. fulltext
spellingShingle Hellard, M.
Rolls, D.
Sacks-Davis, R.
Robins, G.
Pattison, P.
Higgs, Peter
Aitken, C.
McBryde, E.
The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title_full The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title_fullStr The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title_full_unstemmed The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title_short The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
title_sort impact of injecting networks on hepatitis c transmission and treatment in people who inject drugs
url http://hdl.handle.net/20.500.11937/12592